SC-514 - CAS# 354812-17-2 Catalog No.:M6663-2 MLN2238 has an improved pharmacodynamic

MLN2238 has an improved pharmacodynamic profile and antitumor activity compared with bortezomib in both OCI-Ly10 and PHTX22L models

C[N+]1=C2C=CC(=CC2=CC=C1/C=C/C1C=C(C)N(C2C=CC=CC=2)C=1C)N(C)C

33) was higher than that of buspirone (pKi

Currently it is in Phase II/III clinical trials for Hodgkin's lymphoma and advanced breast cancer

SC-514 - CAS# 354812-17-2 Catalog No.:M6663-2 MLN2238 has an improved pharmacodynamicSC 514, CAS No. 354812 17 2, is a selective and reversible inhibitor of IB kinase 2 (IKK2) that may target osteoclastogenesis. SC 514 dose dependently inhibits RANKL induced osteoclastogenesis and induced apoptosis and caspase 3 activation in RAW264. 7 cells. Targeting IKK by SC 514 may be a potential treatment for osteoclast related disorders such as osteoporosis and cancer induced bone loss. Product information CAS Number: 354812 17 2 Molecular